CrownBio Acquires PRECOS

Crown Bioscience, Inc. has acquired Preclinical Oncology Services Ltd. (PRECOS), a preclinical service provider with expertise in oncology. As a result of the acquisition, Crown will be among the largest suppliers of oncology services with a global footprint spanning North America, Europe and Asia Pacific.
 
CrownBio provides translational platforms and drug discovery solutions in the therapeutic areas of oncology and metabolic disease. Headquartered in Santa Clara, CA, the company also has research facilities in Kannapolis, NC, Beijing and Taicang, China. PRECOS provides reproducible, patient-relevant in vivo and in vitro oncology models as a business unit of the University of Nottingham, UK. In 2010 PRECOS became fully independent to provide commercial service to clients.
 
Jean-Pierre Wery, president of Crown Bioscience, remarked, “The acquisition represents the next step in expanding the range of specialized services we offer pharmaceutical and biopharmaceutical customers worldwide. PRECOS has unique clinically relevant models, which reflect the patient situation for each aspect of cancer progression, encompassing pre-cancerous lesions, primary tumors and metastasis.”
 
Neil Rotherham, chairman of PRECOS, added, “The acquisition will enable PRECOS to continue expanding its business as part of a larger organization, giving Crown Bioscience clients access to our unique and growing panel of Patient-Derived Xenograft, orthotopic and metastatic modeling and imaging services. The security of being part of a larger, global and rapidly growing organization will enable us to continue to invest in providing leading-edge model development services to the wider oncology drug discovery community.”